• URB597 (KDS-4103): Enhancing Endocannabinoid Signaling Resea

  2026-05-24

  URB597 (KDS-4103) empowers researchers with consistent, selective FAAH inhibition to probe endocannabinoid signaling in neuroplasticity and pain models. This guide details optimized workflows, troubleshooting, and insights from recent multi-dimensional pain research, bridging bench protocols with translational context.

• Berberrubine Chloride: Applied Protocols in Cancer and Infla

  2026-05-23

  Berberrubine chloride empowers reproducible, multi-target research in oncology and inflammation through well-characterized molecular inhibition and robust in vitro/in vivo protocols. This article bridges experimental workflows, troubleshooting, and translational insights, leveraging both literature and APExBIO’s high-purity reagent.

• Oteseconazole (VT-1161): Transforming Candida Antifungal Res

  2026-05-22

  This article delivers a mechanistic, evidence-backed perspective on Oteseconazole (VT-1161) for translational researchers battling Candida infections. Integrating the latest clinical, experimental, and pipeline insights, it provides strategic guidance for leveraging this selective CYP51 inhibitor in research and clinical development, with a focus on fluconazole resistance and prevention of recurrent vulvovaginal candidiasis.

• Ca2+-Dependent Autophagy and Lysosomal Alkalinization in GBM

  2026-05-22

  The referenced study elucidates how the tetralin derivative NNC-55–0396 induces cell death in glioblastoma by simultaneously triggering Ca2+-dependent autophagy and disrupting lysosomal acidification. These findings advance the understanding of calcium signaling in tumor stress responses and offer mechanistic insights for targeting autophagy in cancer therapy.

• Moesin as a Biomarker of Endothelial Injury in Sepsis: Insig

  2026-05-21

  The reference study establishes moesin (MSN) as a novel biomarker of endothelial injury in sepsis, demonstrating its correlation with clinical severity and mechanistic involvement in vascular dysfunction. These findings illuminate new avenues for evaluating and potentially mitigating endothelial damage in septic patients.

• hiPSC-Derived Intestinal Organoids for Drug Pharmacokinetics

  2026-05-21

  This study introduces an accessible protocol for generating human induced pluripotent stem cell-derived intestinal organoids (hiPSC-IOs) with long-term self-renewal and differentiation capacity. The platform provides a physiologically relevant in vitro model for pharmacokinetic studies, addressing limitations of traditional Caco-2 and animal models.

• Capsaicin Applications: TRPV1 & KDM1A Inhibition in Research

  2026-05-20

  Capsaicin ((E)-Capsaicin) stands out as a unique dual-action tool for both TRPV1 ion channel activation and selective KDM1A/LSD1 inhibition. This deep-dive provides protocol-ready guidance, use-case distinctions, and troubleshooting insights that enable researchers to maximize reproducibility and translational potential in pain, cancer, and inflammation models.

• Berberrubine Chloride: Workflow Innovations for Cancer & Thr

  2026-05-20

  Berberrubine chloride (9-hydroxy-10-methoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium chloride) advances precision research in oncology and cardiovascular models, offering robust multi-target inhibition and metabolic modulation. This guide delivers actionable protocols, troubleshooting insights, and cross-study context for maximizing experimental success with APExBIO’s research grade compound.

• Gemcitabine HCl: Workflow Optimization for Pancreatic Cancer

  2026-05-19

  Gemcitabine HCl stands at the forefront of preclinical pancreatic cancer research, enabling precise DNA replication inhibition and robust tumor growth suppression. This guide explores validated workflows, advanced multianimal imaging integration, and troubleshooting strategies to maximize experimental rigor using APExBIO’s Gemcitabine HCl.

• Primidone (SKU B2120): Precision Tools for TRPM3 & RIPK1 Ass

  2026-05-19

  This article delivers scenario-driven insights into the use of Primidone (SKU B2120) in cell viability, proliferation, and cytotoxicity workflows. It addresses experimental design, protocol optimization, and product reliability, supporting researchers with evidence-based recommendations and actionable data. Discover how APExBIO’s Primidone ensures reliable and reproducible results across neurodegenerative and gynecological models.

• IGF2BP3–FZD1/7 Axis Drives Stemness and Carboplatin Resistan

  2026-05-18

  This study identifies IGF2BP3 as a dominant m6A reader that stabilizes FZD1/7 transcripts, promoting cancer stemness and carboplatin resistance in triple-negative breast cancer (TNBC). The findings define a key RNA-mediated signaling axis, offering mechanistic insight and a therapeutic target to sensitize TNBC to chemotherapy while reducing toxicity.

• Prednisone in Translational Research: Mechanisms, Models, an

  2026-05-18

  This thought-leadership article explores how mechanistic insights into Prednisone’s immunosuppressive and pro-apoptotic actions can be strategically leveraged by translational researchers. By integrating rigorous in vitro modeling, cross-validating with advances in botanical pharmacokinetics, and highlighting APExBIO’s Prednisone offering, we guide teams toward experimental robustness and clinical relevance.

• Carvedilol Phosphate: Advanced Mechanisms in Hepatic IRI Mod

  2026-05-17

  Explore the advanced use of Carvedilol Phosphate as a non-selective beta blocker in hepatic ischemia–reperfusion injury research. This article uncovers novel mechanistic insights and assay parameters, providing deeper context for cardiovascular pharmacology research.

• Prednisone: Unraveling Mechanisms and Solubility for Advance

  2026-05-16

  Delve into the advanced mechanisms of Prednisone, a synthetic corticosteroid, emphasizing its unique cell cycle and apoptotic effects. This article provides in-depth guidance on solubility, assay optimization, and practical research implications distinct from standard protocols.

• Y-27632 Dihydrochloride: Unlocking Organoid Precision throug

  2026-05-15

  Explore how Y-27632 dihydrochloride, a potent ROCK inhibitor, is advancing organoid and stem cell research through high selectivity and innovative assay integration. This in-depth analysis reveals new frontiers in cytoskeletal control and disease modeling.

398 records 7/27 page Previous Next First page 上5页 678910 下5页 Last page